In a recent development, the Drug Regulatory Authority of Pakistan (DRAP) has taken a proactive stance to address concerns surrounding the prices of medicines. Contrary to speculations, DRAP has officially confirmed that there has been no surge in the cost of medicines across the nation.
In a move aimed at providing better healthcare accessibility, the Pakistani government, in collaboration with DRAP, has introduced a selection of 25 new medicines to the market. These medicines, hitherto unregistered within Pakistan, mark a significant stride towards expanding the range of available treatments for the citizens. It’s important to note that these fresh additions to the medical landscape are not subject to any price increase; instead, the government has meticulously set reasonable price points.
Of particular significance is the fact that these new medicines encompass a diverse array of treatment options. This initiative not only addresses the need for affordable medications but also showcases the nation’s commitment to enhancing the overall health and well-being of its citizens.
It’s worth highlighting that the common and widely used medication, simple paracetamol, has remained unaffected by any price adjustments. DRAP reiterates its commitment to ensuring that essential medications remain accessible to all, irrespective of their economic background.